This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Amedisys (AMED) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's What Key Metrics Tell Us About Amedisys (AMED) Q2 Earnings
by Zacks Equity Research
Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amedisys (AMED) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of +10.79% and +2.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Can BrightSpring's Q1 Strength Carry Through 2025 Headwinds?
by Sridatri Sarkar
BTSG faces margin pressure, but strong first-quarter gains in Pharmacy Solution and Provider Services lift confidence.
Here's Why You Should Retain AMED Stock in Your Portfolio for Now
by Zacks Equity Research
Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry.
BrightSpring Soars to All-Time High on Quality Strength: Still a Buy?
by Urmimala Biswas
BTSG stock hits an all-time high with a 120% gain as soaring quality ratings and strong Q1 results fuel investor confidence.
BrightSpring's Care Ratings Climb: Is Its Lead Sustainable?
by Sridatri Sarkar
BTSG boosts care quality with tech upgrades, earning top ratings and patient satisfaction across all segments.
AMED or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMED vs. CHE: Which Stock Is the Better Value Option?
Amedisys (AMED) Down 0.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are Medical Stocks Lagging Amedisys (AMED) This Year?
by Zacks Equity Research
Here is how Amedisys (AMED) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.
Can Revenue Cycle Operations Drive DVA Stock Before Q1 Earnings?
by Zacks Equity Research
Continued strength in revenue cycle operations is likely to have boosted DaVita's top line in the first quarter despite supply challenges weighing on its performance.
AMED Stock Trades Flat Despite Q1 Earnings Beat, Margins Rise
by Zacks Equity Research
Amedisys delivers first-quarter top-line growth across three of its segments, namely Home Health, Hospice and High Acuity Care.
Compared to Estimates, Amedisys (AMED) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amedisys (AMED) Tops Q1 Earnings Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 10.62% and 0%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Amedisys (AMED) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Amedisys (AMED) Up 1.3% Since Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AVAH Surges 45% in Five Days: How to Play the Stock After Earnings?
by Harshit Gupta
AVAH trades at a discount despite growth in payor deals & services. With solid fundamentals amid labor shortages, is it a buy or hold after earnings?
Here's Why You Should Retain AMED Stock in Your Portfolio Now
by Zacks Equity Research
Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry.
AMED Q4 Earnings and Revenues Miss, Margins Dip, Stock Rises
by Zacks Equity Research
Amedisys, for the fourth quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care.
Amedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amedisys (AMED) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of -8.57% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
DVA Q4 Estimates Unchanged Before Earnings: How to Play the Stock?
by Zacks Equity Research
Continued strength in RPT is likely to have boosted DaVita's top line in the fourth quarter despite supply challenges weighing on its performance.
Amedisys (AMED) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.